TheraCryf PLC
Company Profile
Business description
TheraCryf PLC is a biotechnology company developing new medicines for addiction and other neuropsychiatric disorders, areas of unmet medical need within central nervous system (CNS) disorders. The Group's main programme is a novel, benchmark orexin-1 receptor antagonist being developed as a potential treatment for addiction, including binge eating, alcohol, and other substance use disorders. It also has a dopamine transporter (DAT) modulator programme addressing fatigue of brain origin, including fatigue associated with multiple sclerosis, chemotherapy, and narcolepsy. The Group also has an oncology programme in glioblastoma with SFX-01. It operates a capital-light, virtual development model advancing programmes to early clinical or proof-of-concept stage before partnering.
Contact
Congleton Road
Alderley Park
Nether AlderleyCheshireSK10 4TG
GBRT: +44 1625315090
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2027
Employees
9
Stocks News & Analysis
stocks
Overvalued ASX share has overly ambitious profit target
stocks
7 undervalued US stocks that crushed earnings
stocks
Undervalued ASX share hitting on all cylinders
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,018.50 | 146.90 | -1.60% |
| CAC 40 | 8,352.00 | 16.91 | -0.20% |
| DAX 40 | 26,598.64 | 151.31 | -0.57% |
| Dow JONES (US) | 51,608.17 | 739.38 | -1.41% |
| FTSE 100 | 10,881.55 | 21.01 | -0.19% |
| HKSE | 23,458.96 | 294.88 | -1.24% |
| NASDAQ | 24,509.76 | 626.52 | -2.49% |
| Nikkei 225 | 58,935.99 | 726.03 | -1.22% |
| NZX 50 Index | 14,307.63 | 3.86 | 0.03% |
| S&P 500 | 7,416.59 | 145.08 | -1.92% |
| S&P/ASX 200 | 8,902.60 | 142.10 | -1.57% |
| SSE Composite Index | 3,578.26 | 24.31 | -0.67% |